Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$12.48	$10.19	$4.11 ▼ $28.68	$82.16M	2.97	172,788 shs	31,369 shs
GERN Geron	$1.44 +3.6%	$1.44	$1.17 ▼ $5.06	$885.32M	0.64	11.28 million shs	9.92 million shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	5.31 million shs	N/A
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
VKTX Viking Therapeutics	$30.40 +0.7%	$27.53	$18.92 ▼ $81.73	$3.39B	0.62	4.07 million shs	5.62 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	-1.34%	+0.32%	+10.25%	+118.95%	+58,767.92%
GERN Geron	+1.46%	+0.72%	-13.13%	0.00%	-69.32%
MTEM Molecular Templates	0.00%	0.00%	0.00%	0.00%	-99.99%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VKTX Viking Therapeutics	+9.74%	+13.20%	+8.48%	+30.69%	-40.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBRX Forte Biosciences	2.5487 of 5 stars	3.5	4.0	0.0	0.0	0.6	1.7	0.6
GERN Geron	2.8462 of 5 stars	3.4	1.0	0.0	1.3	0.6	1.7	0.6
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	0.513 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
VKTX Viking Therapeutics	3.861 of 5 stars	3.5	1.0	0.0	4.7	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	3.00	Buy	$61.00	388.78% Upside
GERN Geron	2.78	Moderate Buy	$5.06	251.56% Upside
MTEM Molecular Templates	0.00	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	3.00	Buy	$87.15	186.69% Upside

Current Analyst Ratings Breakdown

Latest SPPI, VKTX, FBRX, MTEM, and GERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
5/8/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$4.00 ➝ $1.50
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
GERN Geron	$76.99M	11.91	N/A	N/A	$0.46 per share	3.13
MTEM Molecular Templates	$23.48M	0.00	N/A	N/A	$0.78 per share	0.00
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
GERN Geron	-$174.57M	-$0.21	N/A	N/A	N/A	-119.54%	-47.86%	-26.78%	8/6/2025 (Estimated)
MTEM Molecular Templates	-$8.12M	-$2.70	N/A	N/A	N/A	-61.35%	-260.50%	-46.90%	N/A
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest SPPI, VKTX, FBRX, MTEM, and GERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/7/2025	Q1 2025	GERN Geron	-$0.04	-$0.03	+$0.01	-$0.03	$49.88 million	$39.60 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	5.22	5.22
GERN Geron	0.44	7.87	6.97
MTEM Molecular Templates	N/A	1.56	1.56
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
GERN Geron	73.71%
MTEM Molecular Templates	95.47%
SPPI Spectrum Pharmaceuticals	21.67%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	5.90%
GERN Geron	7.42%
MTEM Molecular Templates	13.90%
SPPI Spectrum Pharmaceuticals	2.70%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
GERN Geron	70	636.92 million	589.66 million	Optionable
MTEM Molecular Templates	260	6.58 million	5.67 million	No Data
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

SPPI, VKTX, FBRX, MTEM, and GERN Headlines

Recent News About These Companies

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

July 9 at 4:17 PM | insidermonkey.com

Financial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 9 at 5:41 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?

July 8 at 4:24 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.

July 8 at 3:24 AM | marketbeat.com

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

July 7 at 3:45 AM | fool.com

August 22nd Options Now Available For Viking Therapeutics (VKTX)

July 5, 2025 | nasdaq.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 4, 2025 | insidertrades.com

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

July 4, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 3, 2025 | zacks.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 3, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells $118,466.82 in Stock

July 3, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Sells 26,889 Shares

July 3, 2025 | marketbeat.com

VKTX - Viking Therapeutics Inc Sustainability - Morningstar

July 3, 2025 | morningstar.comM

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)

July 2, 2025 | theglobeandmail.com

Viking Therapeutics (NASDAQ:VKTX) Shares Up 7.7% - Here's What Happened

July 2, 2025 | marketbeat.com

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

July 2, 2025 | zacks.com

Got $200? 2 Biotech Stocks to Buy and Hold Forever

July 1, 2025 | fool.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

...

June 29, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 27, 2025 | zacks.com

Why This Weight Loss Drug Company's Stock Surged Today

June 26, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

SPPI, VKTX, FBRX, MTEM, and GERN Company Descriptions

Forte Biosciences NASDAQ:FBRX

$12.48 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$12.50 +0.03 (+0.20%)

As of 04:27 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Geron NASDAQ:GERN

$1.44 +0.05 (+3.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 +0.01 (+0.69%)

As of 07:57 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$30.40 +0.21 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$30.39 -0.01 (-0.05%)

As of 08:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time